Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy

Published:2018-04 Issue: Volume:Volume 10 Page:647-652
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Weart Thomas C,Miller Kenneth D,Simone II Charles B

Publisher

Informa UK Limited

Subject

Oncology

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer;Pharmaceutics;2023-04-16

2. Nanomedicine for targeting the lung cancer cells by interpreting the signaling pathways;Journal of Drug Delivery Science and Technology;2022-11

3. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis;BMC Cancer;2022-03-10

4. Advances in Targeted Treatments for NSCLC (Excluding EGFR/ALK/ROS-1/K-Ras);Encyclopedia of Respiratory Medicine;2022

5. Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro;Cancers;2021-03-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP